Active	Status	Sponsor type	Region	Phase	Filter
1 Active 29 Inactive 30 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other Show only owner-sponsored trials	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

1 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
luminespib (AUY922) / Ligand
ACTRN12614000789662: Evaluating a new drug (AUY922) for controlling prostate cancer cell growth using laboratory based outcomes in men with high risk prostate cancer	Not yet recruiting	2	55			The University of Sydney, Cancer Australia	Prostate Cancer